Viewing Study NCT05862194


Ignite Creation Date: 2025-12-25 @ 1:38 AM
Ignite Modification Date: 2025-12-28 @ 12:14 AM
Study NCT ID: NCT05862194
Status: COMPLETED
Last Update Posted: 2023-08-22
First Post: 2023-05-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
Sponsor: Yuhan Corporation
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module